Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:9730319.
doi: 10.1155/2016/9730319. Epub 2016 Jun 5.

Characteristics of Nonmotor Symptoms in Progressive Supranuclear Palsy

Affiliations

Characteristics of Nonmotor Symptoms in Progressive Supranuclear Palsy

Ruwei Ou et al. Parkinsons Dis. 2016.

Abstract

Objectives. To explore the clinical correlates of nonmotor symptoms (NMS) in progressive supranuclear palsy (PSP) and their differences from healthy controls and patients with Parkinson's disease (PD). Methods. Twenty-seven PSP patients, 27 age- and gender-matched healthy controls (HC), and 27 age- and gender-matched PD patients were included for this case-control study. NMS were assessed using the Nonmotor Symptoms Scale (NMSS, including 9 domains). Results. All PSP patients reported NMS. The frequency and severity of "sleep/fatigue," "mood/apathy," "attention/memory," "gastrointestinal," "sexual dysfunction," and "miscellaneous" domains in PSP group were significantly higher than those in HC group (P < 0.05). The frequency of "mood/apathy," "attention/memory," and "sexual dysfunction" domains and the severity of "attention/memory" and "gastrointestinal" domains in PSP group were significantly higher than those in PD group (P < 0.05). The "attention/memory" domain in PSP had a significant but weak-to-moderate correlation with age (R = 0.387, P = 0.046) and onset age (R = 0.406, P = 0.036). Conclusions. NMS are common in PSP patients. Patients with PSP seem to be subjected to more frequent and severe specific NMS compared to healthy aging subjects and PD patients. Older PSP patients and late-onset patients are likely to be subjected to cognitive decline.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schrag A., Ben-Shlomo Y., Quinn N. P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. The Lancet. 1999;354(9192):1771–1775. doi: 10.1016/s0140-6736(99)04137-9. - DOI - PubMed
    1. Litvan I. Update on epidemiological aspects of progressive supranuclear palsy. Movement Disorders. 2003;18(supplement 6):S43–S50. doi: 10.1002/mds.10579. - DOI - PubMed
    1. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology. 1996;47(1):1–9. doi: 10.1212/wnl.47.1.1. - DOI - PubMed
    1. Pekmezović T., Ječmenica-Lukić M., Petrović I., Špica V., Tomić A., Kostić V. S. Quality of life in patients with progressive supranuclear palsy: one-year follow-up. Journal of Neurology. 2015;262(9):2042–2048. doi: 10.1007/s00415-015-7815-3. - DOI - PubMed
    1. Gerstenecker A., Duff K., Mast B., Litvan I. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Research. 2013;210(3):1205–1210. doi: 10.1016/j.psychres.2013.08.045. - DOI - PMC - PubMed

LinkOut - more resources